HEADER HYDROLASE 02-MAR-03 1ONY TITLE OXALYL-ARYL-AMINO BENZOIC ACID INHIBITORS OF PTP1B, COMPOUND 17 COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEIN-TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: PTP1B CATALYTIC DOMAIN; COMPND 5 SYNONYM: PROTEIN-TYROSINE PHOSPHATASE 1B, PTP-1B; COMPND 6 EC: 3.1.3.48; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PTPN1 OR PTP1B; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(D33)/PTPASE 1B; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PT7-7 KEYWDS PROTEIN TYROSINE PHOSPHATASE, OXALYL-ARYL-AMINO BENZOIC ACID KEYWDS 2 INHIBITOR, HYDROLASE EXPDTA X-RAY DIFFRACTION AUTHOR G.LIU,B.G.SZCZEPANKIEWICZ,Z.PEI,D.A.JANOWICH,Z.XIN,P.J.HADJUK,C.ABAD- AUTHOR 2 ZAPATERO,H.LIANG,C.W.HUTCHINS,S.W.FESIK,S.J.BALLARON,M.A.STASHKO, AUTHOR 3 T.LUBBEN,A.K.MIKA,B.A.ZINKER,J.M.TREVILLYAN,M.R.JIROUSEK REVDAT 4 16-AUG-23 1ONY 1 REMARK REVDAT 3 11-OCT-17 1ONY 1 REMARK REVDAT 2 24-FEB-09 1ONY 1 VERSN REVDAT 1 20-MAY-03 1ONY 0 JRNL AUTH G.LIU,B.G.SZCZEPANKIEWICZ,Z.PEI,D.A.JANOWICH,Z.XIN, JRNL AUTH 2 P.J.HADJUK,C.ABAD-ZAPATERO,H.LIANG,C.W.HUTCHINS,S.W.FESIK, JRNL AUTH 3 S.J.BALLARON,M.A.STASHKO,T.LUBBEN,A.K.MIKA,B.A.ZINKER, JRNL AUTH 4 J.M.TREVILLYAN,M.R.JIROUSEK JRNL TITL DISCOVERY AND STRUCTURE-ACTIVITY RELATIONSHIP OF JRNL TITL 2 OXALYLARYLAMINOBENZOIC ACIDS AS INHIBITORS OF PROTEIN JRNL TITL 3 TYROSINE PHOSPHATASE 1B JRNL REF J.MED.CHEM. V. 46 2093 2003 JRNL REFN ISSN 0022-2623 JRNL PMID 12747781 JRNL DOI 10.1021/JM0205696 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH Z.XIN,T.K.OOST,C.ABAD-ZAPATERO,P.J.HAJDUK,Z.PEI, REMARK 1 AUTH 2 B.G.SZCZEPANKIEWICZ,C.W.HUTCHINS,S.J.BALLARON,M.A.STASHKO, REMARK 1 AUTH 3 T.LUBBEN,J.M.TREVILLYAN,M.R.JIROUSEK,G.LIU REMARK 1 TITL POTENT, SELECTIVE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE REMARK 1 TITL 2 1B REMARK 1 REF BIOORG.MED.CHEM.LETT. V. 13 1887 2003 REMARK 1 REFN ISSN 0960-894X REMARK 1 DOI 10.1016/S0960-894X(03)00302-0 REMARK 1 REFERENCE 2 REMARK 1 AUTH B.G.SZCZEPANKIEWICZ,G.LIU,P.J.HAJDUK,C.ABAD-ZAPATERO,Z.PEI, REMARK 1 AUTH 2 Z.XIN,T.LUBBEN,J.M.TREVILLYAN,M.A.STASHKO,S.J.BALLARON, REMARK 1 AUTH 3 H.LIANG,F.HUANG,C.W.HUTCHINS,S.W.FESIK,M.R.JIROUSEK REMARK 1 TITL POTENT, SELECTIVE PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR REMARK 1 TITL 2 USING A LINKED-FRAGMENT STRATEGY REMARK 1 REF J.AM.CHEM.SOC. V. 125 4087 2003 REMARK 1 REFN ISSN 0002-7863 REMARK 1 DOI 10.1021/JA0296733 REMARK 2 REMARK 2 RESOLUTION. 2.15 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX 2000 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.15 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 17.44 REMARK 3 DATA CUTOFF (SIGMA(F)) : 2.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 86.5 REMARK 3 NUMBER OF REFLECTIONS : 23083 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.206 REMARK 3 R VALUE (WORKING SET) : 0.194 REMARK 3 FREE R VALUE : 0.220 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 10.000 REMARK 3 FREE R VALUE TEST SET COUNT : 2308 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.005 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : NULL REMARK 3 FREE R VALUE (NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 26709 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 10 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.15 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.23 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 69.80 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1637 REMARK 3 BIN R VALUE (WORKING SET) : 0.2090 REMARK 3 BIN FREE R VALUE : 0.2410 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 11.30 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 208 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.017 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2301 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 41 REMARK 3 SOLVENT ATOMS : 312 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 33.30 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 36.20 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 3.25000 REMARK 3 B22 (A**2) : 3.25000 REMARK 3 B33 (A**2) : -6.50000 REMARK 3 B12 (A**2) : 4.54000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.28 REMARK 3 ESD FROM SIGMAA (A) : 0.18 REMARK 3 LOW RESOLUTION CUTOFF (A) : 6.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.27 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.18 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.007 REMARK 3 BOND ANGLES (DEGREES) : 1.300 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 22.70 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.720 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.660 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.610 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.630 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.860 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.39 REMARK 3 BSOL : 73.04 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : 588.PAR REMARK 3 PARAMETER FILE 3 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : 588.TOP REMARK 3 TOPOLOGY FILE 3 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: RESIDUE CYS215, LISTED IN REMARK 500, REMARK 3 CORRESPONDS TO THE ACTIVE SITE CYS WHICH IS KNOWN TO BE IN A REMARK 3 STRAINED CONFORMATION IN THIS CLASS OF ENZYMES. STRAINED REMARK 3 CONFORMATION OF GLY259 IS CAUSED BY THE PRESENCE OF THE REMARK 3 INHIBITOR IN THE ACTIVE SITE AND IN THE VICINITY OF GLN262. REMARK 4 REMARK 4 1ONY COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 17-MAR-03. REMARK 100 THE DEPOSITION ID IS D_1000018485. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 01-AUG-00 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.1 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU RU300 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MAR REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 30332 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 81.3 REMARK 200 DATA REDUNDANCY : 4.800 REMARK 200 R MERGE (I) : 0.06500 REMARK 200 R SYM (I) : 0.06500 REMARK 200 FOR THE DATA SET : 16.9000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.07 REMARK 200 COMPLETENESS FOR SHELL (%) : 96.5 REMARK 200 DATA REDUNDANCY IN SHELL : 4.10 REMARK 200 R MERGE FOR SHELL (I) : 0.57100 REMARK 200 R SYM FOR SHELL (I) : 0.57100 REMARK 200 FOR SHELL : 2.100 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNX 2000 REMARK 200 STARTING MODEL: PDB ENTRY 1TYR AND INITIAL INTERNAL REFINEMENT REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 61.83 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.22 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PRECIPITATION BUFFER: 100 MM HEPES, REMARK 280 0.2 M MAGNESIUM ACETATE, 14% PEG8000, PH 7.1, VAPOR DIFFUSION, REMARK 280 HANGING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 31 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+1/3 REMARK 290 3555 -X+Y,-X,Z+2/3 REMARK 290 4555 Y,X,-Z REMARK 290 5555 X-Y,-Y,-Z+2/3 REMARK 290 6555 -X,-X+Y,-Z+1/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 35.11733 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 70.23467 REMARK 290 SMTRY1 4 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 4 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 5 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 70.23467 REMARK 290 SMTRY1 6 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 35.11733 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1 REMARK 465 SER A 285 REMARK 465 SER A 286 REMARK 465 VAL A 287 REMARK 465 GLN A 288 REMARK 465 ASP A 289 REMARK 465 GLN A 290 REMARK 465 TRP A 291 REMARK 465 LYS A 292 REMARK 465 GLU A 293 REMARK 465 LEU A 294 REMARK 465 SER A 295 REMARK 465 HIS A 296 REMARK 465 GLU A 297 REMARK 465 ASP A 298 REMARK 465 LEU A 299 REMARK 465 GLU A 300 REMARK 465 PRO A 301 REMARK 465 PRO A 302 REMARK 465 PRO A 303 REMARK 465 GLU A 304 REMARK 465 HIS A 305 REMARK 465 ILE A 306 REMARK 465 PRO A 307 REMARK 465 PRO A 308 REMARK 465 PRO A 309 REMARK 465 PRO A 310 REMARK 465 ARG A 311 REMARK 465 PRO A 312 REMARK 465 PRO A 313 REMARK 465 LYS A 314 REMARK 465 ARG A 315 REMARK 465 ILE A 316 REMARK 465 LEU A 317 REMARK 465 GLU A 318 REMARK 465 PRO A 319 REMARK 465 HIS A 320 REMARK 465 ASN A 321 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ASP A 284 CA C O CB CG OD1 OD2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 63 -92.99 -60.33 REMARK 500 CYS A 215 -120.11 -140.01 REMARK 500 ILE A 219 -36.12 -140.57 REMARK 500 ILE A 261 99.07 80.35 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 588 A 322 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1NL9 RELATED DB: PDB REMARK 900 POTENT, SELECTIVE PROTEIN TYROSINE PHOSPHATASE INHIBITORS USING A REMARK 900 LINKED-FRAGMENT STRATEGY COMPLEXED WITH COMPOUND 12 REMARK 900 RELATED ID: 1NNY RELATED DB: PDB REMARK 900 POTENT, SELECTIVE PROTEIN TYROSINE PHOSPHATASE INHIBITORS USING A REMARK 900 LINKED-FRAGMENT STRATEGY COMPLEXED WITH COMPOUND 23 REMARK 900 RELATED ID: 1NO6 RELATED DB: PDB REMARK 900 POTENT, SELECTIVE PROTEIN TYROSINE PHOSPHATASE INHIBITORS USING A REMARK 900 LINKED-FRAGMENT STRATEGY COMPLEXED WITH COMPOUND 5 REMARK 900 RELATED ID: 1NZ7 RELATED DB: PDB REMARK 900 POTENT, SELECTIVE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B REMARK 900 COMPLEXED WITH COMPOUND 19 REMARK 900 RELATED ID: 1ONZ RELATED DB: PDB REMARK 900 POTENT, SELECTIVE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B REMARK 900 COMPLEXED WITH COMPOUND 8B DBREF 1ONY A 1 321 UNP P18031 PTN1_HUMAN 1 321 SEQRES 1 A 321 MET GLU MET GLU LYS GLU PHE GLU GLN ILE ASP LYS SER SEQRES 2 A 321 GLY SER TRP ALA ALA ILE TYR GLN ASP ILE ARG HIS GLU SEQRES 3 A 321 ALA SER ASP PHE PRO CYS ARG VAL ALA LYS LEU PRO LYS SEQRES 4 A 321 ASN LYS ASN ARG ASN ARG TYR ARG ASP VAL SER PRO PHE SEQRES 5 A 321 ASP HIS SER ARG ILE LYS LEU HIS GLN GLU ASP ASN ASP SEQRES 6 A 321 TYR ILE ASN ALA SER LEU ILE LYS MET GLU GLU ALA GLN SEQRES 7 A 321 ARG SER TYR ILE LEU THR GLN GLY PRO LEU PRO ASN THR SEQRES 8 A 321 CYS GLY HIS PHE TRP GLU MET VAL TRP GLU GLN LYS SER SEQRES 9 A 321 ARG GLY VAL VAL MET LEU ASN ARG VAL MET GLU LYS GLY SEQRES 10 A 321 SER LEU LYS CYS ALA GLN TYR TRP PRO GLN LYS GLU GLU SEQRES 11 A 321 LYS GLU MET ILE PHE GLU ASP THR ASN LEU LYS LEU THR SEQRES 12 A 321 LEU ILE SER GLU ASP ILE LYS SER TYR TYR THR VAL ARG SEQRES 13 A 321 GLN LEU GLU LEU GLU ASN LEU THR THR GLN GLU THR ARG SEQRES 14 A 321 GLU ILE LEU HIS PHE HIS TYR THR THR TRP PRO ASP PHE SEQRES 15 A 321 GLY VAL PRO GLU SER PRO ALA SER PHE LEU ASN PHE LEU SEQRES 16 A 321 PHE LYS VAL ARG GLU SER GLY SER LEU SER PRO GLU HIS SEQRES 17 A 321 GLY PRO VAL VAL VAL HIS CYS SER ALA GLY ILE GLY ARG SEQRES 18 A 321 SER GLY THR PHE CYS LEU ALA ASP THR CYS LEU LEU LEU SEQRES 19 A 321 MET ASP LYS ARG LYS ASP PRO SER SER VAL ASP ILE LYS SEQRES 20 A 321 LYS VAL LEU LEU GLU MET ARG LYS PHE ARG MET GLY LEU SEQRES 21 A 321 ILE GLN THR ALA ASP GLN LEU ARG PHE SER TYR LEU ALA SEQRES 22 A 321 VAL ILE GLU GLY ALA LYS PHE ILE MET GLY ASP SER SER SEQRES 23 A 321 VAL GLN ASP GLN TRP LYS GLU LEU SER HIS GLU ASP LEU SEQRES 24 A 321 GLU PRO PRO PRO GLU HIS ILE PRO PRO PRO PRO ARG PRO SEQRES 25 A 321 PRO LYS ARG ILE LEU GLU PRO HIS ASN HET 588 A 322 41 HETNAM 588 2-{[2-(2-CARBAMOYL-VINYL)-4-(2-METHANESULFONYLAMINO-2- HETNAM 2 588 PENTYLCARBAMOYL-ETHYL)-PHENYL]-OXALYL-AMINO}-BENZOIC HETNAM 3 588 ACID HETSYN 588 COMPOUND 17 FORMUL 2 588 C27 H32 N4 O9 S FORMUL 3 HOH *312(H2 O) HELIX 1 1 GLU A 2 SER A 13 1 12 HELIX 2 2 SER A 15 ALA A 27 1 13 HELIX 3 3 CYS A 32 LEU A 37 1 6 HELIX 4 4 PRO A 38 ASN A 44 5 7 HELIX 5 5 PHE A 52 ARG A 56 5 5 HELIX 6 6 THR A 91 GLN A 102 1 12 HELIX 7 7 PRO A 188 SER A 201 1 14 HELIX 8 8 GLY A 220 ARG A 238 1 19 HELIX 9 9 ASP A 240 VAL A 244 5 5 HELIX 10 10 ASP A 245 ARG A 254 1 10 HELIX 11 11 THR A 263 MET A 282 1 20 SHEET 1 A 8 ALA A 69 MET A 74 0 SHEET 2 A 8 ARG A 79 THR A 84 -1 O TYR A 81 N ILE A 72 SHEET 3 A 8 VAL A 211 HIS A 214 1 O VAL A 213 N ILE A 82 SHEET 4 A 8 GLY A 106 MET A 109 1 N VAL A 108 O VAL A 212 SHEET 5 A 8 THR A 168 TYR A 176 1 O PHE A 174 N MET A 109 SHEET 6 A 8 TYR A 153 ASN A 162 -1 N THR A 154 O HIS A 175 SHEET 7 A 8 LEU A 140 ILE A 149 -1 N SER A 146 O GLN A 157 SHEET 8 A 8 MET A 133 PHE A 135 -1 N MET A 133 O LEU A 142 SHEET 1 B 2 MET A 114 GLU A 115 0 SHEET 2 B 2 SER A 118 LEU A 119 -1 O SER A 118 N GLU A 115 SITE 1 AC1 19 TYR A 46 ASP A 48 LYS A 120 CYS A 215 SITE 2 AC1 19 SER A 216 ALA A 217 GLY A 218 ILE A 219 SITE 3 AC1 19 GLY A 220 ARG A 221 GLN A 262 THR A 263 SITE 4 AC1 19 GLN A 266 GLY A 283 HOH A 524 HOH A 531 SITE 5 AC1 19 HOH A 540 HOH A 598 HOH A 629 CRYST1 89.015 89.015 105.352 90.00 90.00 120.00 P 31 2 1 6 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.011234 0.006486 0.000000 0.00000 SCALE2 0.000000 0.012972 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009492 0.00000